PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-37.55%
Negative net income growth indicates shrinking profitability. Benjamin Graham would label it a concern unless explained by temporary factors.
14.84%
D&A 10-15% yoy – Potential drag on reported income. Howard Marks would question if ROI on assets justifies it.
No Data
No Data available this quarter, please select a different quarter.
0.81%
SBC up to 10% yoy – Acceptable. Seth Klarman would expect net income to grow enough to offset the mild dilution.
106.29%
Working capital above 30% yoy – Very high. Philip Fisher would demand clarity on whether the buildup is strategic or signals inefficiency.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
81.80%
Above 30% yoy – Major jump. Philip Fisher would demand details on these miscellaneous lines to ensure transparency.
No Data
No Data available this quarter, please select a different quarter.
9.51%
Operating cash flow growth 5-10% – Moderate. Peter Lynch would hope expansions can further boost core cash generation.
38.16%
CapEx above 15% yoy – Significant. Philip Fisher would demand strong evidence of high-ROI projects to offset the spending.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
38.16%
Above 15% yoy – Heavy. Philip Fisher would require evidence these invests drive future returns and do not hamper free cash flow too much.
No Data
No Data available this quarter, please select a different quarter.
1171.17%
Issuance above 15% yoy – Significant equity raise. Philip Fisher would require a very compelling reason to risk heavy shareholder dilution.
No Data
No Data available this quarter, please select a different quarter.